Literature DB >> 28583381

Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae.

Marlene Fredborg1, Teis E Sondergaard2, Mikala Wang3.   

Abstract

The increasing emergence of carbapenemase-producing Enterobacteriaceae poses a considerable threat to global health as only limited treatment options are available and has therefore led to efforts to discover antibiotic combination regimens effective. The aim of this study was to evaluate in vitro synergistic activity of 10 meropenem double and triple combinations against the 5 most frequently encountered carbapenemases-producing Enterobacteriaceae. Broth microdilution assays showed that the meropenem and ertapenem combination was the most efficient regimen of the double combinations tested (>5-log2 fold decrease). The triple combination of meropenem, polymyxin and rifampin exhibited highest synergistic activity of the triple combinations. The divergent reports on synergistic activity of antibiotic combinations suggest that it may not be possible to predict synergy based on carbapenemase type alone. Consequently, we recommend that in vitro evaluation of synergistic activity of antibiotic combinations against carbapenemase-producing Enterobacteriaceae is performed on every isolate to ensure effective treatment regimens.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotics; Carbapenem resistance; Klebsiella pneumoniae; Time-lapse microscopy

Mesh:

Substances:

Year:  2017        PMID: 28583381     DOI: 10.1016/j.diagmicrobio.2017.04.015

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

Review 1.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

2.  When Combined with Colistin, an Otherwise Ineffective Rifampicin-Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Authors:  Eva Armengol; Teresa Asunción; Miguel Viñas; Josep Maria Sierra
Journal:  Microorganisms       Date:  2020-01-08

3.  [Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

Review 4.  OXA-48 Carbapenemase-Producing Enterobacterales in Spanish Hospitals: An Updated Comprehensive Review on a Rising Antimicrobial Resistance.

Authors:  Mario Rivera-Izquierdo; Antonio Jesús Láinez-Ramos-Bossini; Carlos Rivera-Izquierdo; Jairo López-Gómez; Nicolás Francisco Fernández-Martínez; Pablo Redruello-Guerrero; Luis Miguel Martín-delosReyes; Virginia Martínez-Ruiz; Elena Moreno-Roldán; Eladio Jiménez-Mejías
Journal:  Antibiotics (Basel)       Date:  2021-01-18

Review 5.  How to manage KPC infections.

Authors:  Matteo Bassetti; Maddalena Peghin
Journal:  Ther Adv Infect Dis       Date:  2020-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.